Effectiveness and tolerability in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study

被引:8
|
作者
Bae, Charles J. [1 ]
Zee, Phyllis C. [2 ]
Leary, Eileen B. [3 ]
Fuller, Douglas S. [4 ]
Macfadden, Wayne [4 ,6 ]
Candler, Shawn [4 ]
Steininger, Teresa L. [3 ]
Husain, Aatif M. [5 ]
机构
[1] Univ Penn, Penn Med, Philadelphia, PA USA
[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[3] Jazz Pharmaceut, Palo Alto, CA USA
[4] Jazz Pharmaceut, Philadelphia, PA USA
[5] Duke Univ, Med Ctr, Durham, NC USA
[6] 2005 Market St, Philadelphia, PA 19103 USA
关键词
Narcolepsy; Excessive daytime sleepiness; Epworth Sleepiness Scale; Cataplexy; Sodium oxybate; Low -sodium oxybate; BLOOD-PRESSURE; WITHDRAWAL; BURDEN;
D O I
10.1016/j.sleep.2023.05.023
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: The Transition Experience of persons with Narcolepsy taking Oxybate in the Real-world (TENOR) study was conducted to provide real-world insight into the experience of people with narcolepsy switching from sodium oxybate (SXB) to low-sodium oxybate (LXB; 92% less sodium than SXB). Methods: TENOR is a patient-centric, prospective, observational, virtual-format study. Participants were adults with narcolepsy (type 1 or 2) who were transitioning from SXB to LXB treatment (& PLUSMN;7 days from LXB initiation). Effectiveness and tolerability data were collected online from baseline (taking SXB) through 21 weeks (taking LXB) via daily and weekly diaries and questionnaires, including the Epworth Sleepiness Scale (ESS), the Functional Outcomes of Sleep Questionnaire, short version (FOSQ-10), and the British Columbia Cognitive Complaints Inventory (BC-CCI). Results: TENOR participants (N = 85) were 73% female with a mean (SD) age of 40.3 (13.0) years. Mean (SD) ESS scores decreased numerically throughout the transition from SXB to LXB (baseline: 9.9 [5.2]; week 21: 7.5 [4.7]), with 59.5% and 75.0% of participants having scores in the normal range (& LE;10) at baseline and week 21, respectively. Mean (SD) FOSQ-10 scores (baseline: 14.4 [3.4]; week 21: 15.2 [3.2]) and BC-CCI scores (baseline: 6.1 [4.4]; week 21: 5.0 [4.3]) also remained stable. The most common symptoms related to tolerability reported by participants at baseline were sleep inertia, hyperhidrosis, and dizziness (45.2%, 40.5%, and 27.4%, respectively), which decreased in prevalence by week 21 (33.8%, 13.2%, and 8.8%, respectively). Conclusions: Findings from TENOR confirm maintenance of effectiveness and tolerability when transitioning from SXB to LXB treatment. & COPY; 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:65 / 74
页数:10
相关论文
共 50 条
  • [21] Dosing Optimization of Low-Sodium Oxybate in Narcolepsy and Idiopathic Hypersomnia in Adults: Consensus Recommendations
    Morse, Anne Marie
    Bogan, Richard K.
    Roy, Asim
    Thorpy, Michael J.
    NEUROLOGY AND THERAPY, 2024, 13 (03) : 785 - 807
  • [22] Increased Risk of New-Onset Hypertension in Patients With Narcolepsy Initiating Sodium Oxybate: A Real-World Study
    Ben-Joseph, Rami H.
    Somers, Virend K.
    Black, Jed
    D'Agostino, Ralph B.
    Davis, Mat
    Macfadden, Wayne
    Mues, Katherine E.
    Jackson, Clark
    Ni, Weiyi
    Cook, Michael N.
    White, William B.
    MAYO CLINIC PROCEEDINGS, 2024, 99 (11) : 1710 - 1721
  • [23] Low-sodium oxybate improved symptoms in adults with narcolepsy with cataplexy: a plain language summary of publication
    Bogan, Richard K.
    Foldvary-Schaefer, Nancy
    Macfadden, Wayne
    Gow, Monica
    Thorpy, Michael J.
    FUTURE NEUROLOGY, 2024, 18 (04)
  • [24] Monitoring sodium oxybate abuse in the real-world: active and spontaneous surveillance
    Reynolds, Kate
    Black, Joshua C.
    Olson, Richard A.
    Bowman, Jill
    Dart, Richard C.
    CLINICAL TOXICOLOGY, 2024, 62 : 55 - 56
  • [25] BLOOD PRESSURE CHANGES AFTER TREATMENT WITH LOW-SODIUM OXYBATE IN OXYBATE-NAIVE PATIENTS WITH NARCOLEPSY OR IDIOPATHIC HYPERSOMNIA: A POST HOC ANALYSIS
    Macfadden, W.
    Candler, S.
    Fuller, D. S.
    Measey, T. J.
    White, W. B.
    SLEEP MEDICINE, 2024, 115 : 208 - 208
  • [26] Long-term Safety During a Clinical Trial of Low-Sodium Oxybate in Participants With Narcolepsy With Cataplexy
    Bogan, Richard
    Foldvary-Schaefer, Nancy
    Skowronski, Roman
    Chen, Abby
    NEUROLOGY, 2023, 100 (17)
  • [27] Patient Preference and Nocturnal Experience With Sodium Oxybate Treatment for Narcolepsy: Interim Data From RESTORE
    Roy, Asim
    Harsh, John
    Ajayi, Akinyemi
    Stern, Thomas
    Seiden, David
    Dubow, Jordan
    NEUROLOGY, 2022, 98 (18)
  • [28] PATIENT PREFERENCE AND NOCTURNAL EXPERIENCE WITH SODIUM OXYBATE TREATMENT FOR NARCOLEPSY: INTERIM DATA FROM RESTORE
    Roy, Asim
    Harsh, John
    Ajayi, Akinyemi
    Stern, Thomas
    Seiden, David
    Dubow, Jordan
    SLEEP, 2022, 45 : A178 - A179
  • [29] Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy
    Bogan, Richard K.
    Foldvary-Schaefer, Nancy
    Skowronski, Roman
    Chen, Abby
    Thorpy, Michael J.
    CNS DRUGS, 2023, 37 (04) : 323 - 335
  • [30] Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy
    Richard K. Bogan
    Nancy Foldvary-Schaefer
    Roman Skowronski
    Abby Chen
    Michael J. Thorpy
    CNS Drugs, 2023, 37 : 323 - 335